Responding to the publication the Care Quality Commission’s annual State of Care report, Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association, said: "Today's CQC report underlines the NHS is under increasing pressure on its services both in terms of patient demand as well as the need to recruit and retain staff. With budgets being so stretched, it is vital that areas of efficiency and value are prioritised. Use of generic medicines already saves the NHS on average more than £13billion every year with prices among the lowest in Europe. Biosimilar medicines have the opportunity to deliver additional significant value and cost savings to the NHS now and in the future. This will provide access to treat more patients as well as fund specialist nurses for example."